Pfizer sends 'enhanced' COVID shot to clinic under strategy for next generation of vaccines Editas notches milestones for sickle cell disease therapy as FDA lifts partial clinical hold BMS-Ambrx collab runs out of steam after FA relaxin med canned Sponsored: Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb Versant biotechs hand AbCellera antibody discovery wish list as part of multi-year deal with the VC shop Investor pleads guilty to insider trading in Alzheimer's biotech Cidara Therapeutics bags $30M cash in Melinta licensing deal, submits antifungal for FDA review Martin Shkreli wants to be dealt back into the biopharma game, and now he's betting on the blockchain Could the FTC block a Merck-Seagen merger? M&A consultant says no Humana's Q2 profits grow nearly 20% year over year to $696M Medable forges pact with device developer Withings Health Solutions 3M to peel off $8B healthcare business into standalone public company With ominous FDA talks, ObsEva scraps lead women's health drug, plots layoffs in major restructuring Featured Story | By James Waldron Pfizer just raised the stakes of the COVID-19 vaccine business. The Big Pharma has launched a midstage trial of the first in a series of next-generation, variant-busting vaccines that the drugmaker is working on alongside BioNTech. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Editas Medicine has confirmed that a gene editing therapy for sickle cell disease has successfully engrafted into the first patient dosed in a phase 1/2 trial. The gene editing company also announced that a partial clinical hold on the efficacy portion of the RUBY trial for EDIT-301 has now been lifted. read more By Max Bayer More than 10 years after Bristol Myers Squibb and Ambrx teamed up to develop a couple of programs in type 2 diabetes and heart failure, prospects from the partnership have washed away. read more Sponsored by: PathAI Learn how Bristol Myers Squibb is unlocking new insights in translational research and development by transforming pathology with artificial intelligence. read more By Nick Paul Taylor Versant Ventures has enlisted AbCellera as its antibody discovery house band. Off the back of its key role in the development of Eli Lilly’s COVID-19 antibody, AbCellera is set to provide Versant with candidates for multiple targets selected by the VC shop’s portfolio of biotechs. read more By Nick Paul Taylor A financial services professional has pleaded guilty to insider trading of shares in a clinical-stage biotech. The plea relates to allegations that George Haywood avoided a loss of at least $179,000 by selling shares in Neurotrope after learning the biotech, now known as Synaptogenix, was planning a stock offering. read more By Gabrielle Masson After submitting its antifungal drug rezafungin for FDA review, Cidara Therapeutics is handing off exclusive U.S. licensing rights to Melinta Therapeutics in exchange for $30 million upfront. read more By Conor Hale Two months fresh out of prison—and despite a federal judge banning the famous “pharma bro” from working in the drug industry for the rest of his life—Martin Shkreli is looking to get right back in the mix. read more By Kevin Dunleavy Many in the biopharma industry are under the assumption that the FTC will tighten the screws on mergers and acquisitions, especially large ones like Merck and Seagen that are under consideration. But one M&A industry consultant doesn’t believe the FTC has the legal standing to challenge such mergers. read more By Paige Minemyer The results surpassed Wall Street analysts' expectations on both profit and revenue, according to Zacks Investment Research. read more By Gareth Macdonald Trial software firm Medable has partnered with medical device developer Withings Health Solutions in a move intended to boost its decentralized study business. read more By Andrea Park Much like the mythical hydra, when 3M is sliced apart in the coming months, two separate companies will crop up in its place. read more By Angus Liu An approval decision for ObsEva's uterine fibroids candidate, linzagolix, isn’t likely to happen on time. After getting that bleak hint from the FDA, women’s health specialist ObsEva is taking a sharp turn. read more Resources Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Lumanity Join us, as we explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene therapy space. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 